Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
45–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female out-patients \>/= 45 years
Subjects suffering from chronic bronchitis
FEV1\</= 70% and FEV1/FVC \</= 70% predicted from age, height and sex
No documented episode of AECB (requiring treatment) within 6 weeks of randomization and not experiencing an exacerbation at the time of screening
Sputum production on most days, even when exacerbation free
Subjects presented with at least two documented (i.e. requiring antibiotics and/or systemic steroid administration) acute exacerbation episodes during the last 12 monthsIf receiving chronic therapy with inhaled long acting bronchodilators and/or inhaled or systemic steroids, the treatment must have remained stable for the preceding 6 weeks prior to screening
Smoking history of at least 20 pack-years
Subjects willing and able to give fully informed written consent
You may not be if
Subjects with contra-indications to moxifloxacin- Known bronchial carcinoma, pulmonary tuberculosis, cystic fibrosis, documented chronic bronchial asthma or diffuse bronchiectasis- Subjects who are actively participating in intensive pulmonary rehabilitation programs
Subjects with a known history of chronic colonization of pathogenic organisms resistant to moxifloxacin, e.g. Pseudomonas spp, MRSA
No systemic or inhaled antibiotic therapy during the 6 weeks prior to screening and any long term antibiotic usage
Subjects requiring home ventilatory support for COPD and those who have a tracheostomy in situ (subjects requiring home/potable oxygen therapy or CPAP for sleep apnea can be included)
